Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Same old same old. LMBO. Some things never change. Felt like talking to myself as I wanted to feel what it is like, since many here do. Only difference is I did it under my one and only handle. And theoretically, we could go another 2 years with no bad news and you'd still be good.
Again, never really address the specific topics at all. Just generic it's good it's good it's good. Pretty much every point you have made has had excellent thoughts that are contrary to your wonderful thoughts on the company. Specific ones with actual things to back it up. Sorry you are unable to give a rebuttal that points to anything with factual evidence. And truly I don't blame you as there is truly little to go by except things that have been around for quite some time, with little or no update as our leaders that you love, are too pathetic to face shareholders and put out absolutely ridiculous, laughable claims in their letter to shareholders. Or do you believe they made most milestones. LMBO. But they're great at giving themselves huge bonuses, unlike I have ever seen for any "baby biotech" as you put it.
And by the way, my daddy it trying to buy 200,000 shares of Pluristem. Oh ya. But my Daddy's trying to buy 300,000. LMBOx200,000-193,000. You know why.
Hi Scott,
I must say I have to agree with myself. Over and over and over again on the same exact thing. I think recordzz Are being broken on how many timezz the same thing can be said and then be praised. Day after day. I sure hope the one day wonder stays that way. Could you imagine seeing it multiple times a day. Just exchange numbers already and take it private. Please!!!!
Never a bad comment or even a comment on the actual dissuasion. Just keep using the same lame excuse...he huwts my feewings. Boohoo. Pathetic. LMBOx200,000-193,000. Bought the last mini pump again. Some people never learn.
Everything could be ask management. For any company. But you want to make claims on Meso's trial based on reading an article. All in an attempt to discredit Meso's management, but when one comes that questions ours, you tell me to ask management. The points I make seem reasonable don't you think.
I am just countering your arguments with things that are out there. At least you are responding, which opens the door for discussion. Contrary to most that just state the zame thing over and over.
People may not like the way I come across. But given the lack of legitimate responses to any of the valid questions that come across, yet praise a Lonza partnership post, oh well. I have been here a long one and sick of this stock going no where. There are reasons it isn't, and many of the so called negative posts, are the most likely reason. They are substantiated with facts or logical explanations to back them up for the most part. At least that's what I try to do. To just say no bad news yet is a copout, no matter how you look at it.
I want nothing more than this company to succeed, but with each passing quarter and the eternal silence of our leaders, my hope fades. If nothing substantial comes before AGM, I hope the whole lot are removed. Doubt that will happen but we will see.
If they were good enough for our presentation, why were these points not put in the "gold standard" clinical trials? You like that we will see these, so they must be good points right? Will the fda take i to account they are in our presentation? Can these items be looked at after the fact? Was is our management that decided to leave these out of the trial design? All of this couldn't be due to our experience could it?
And with regards to CLI, again I am not necessarily meaning off label. Just something in regards to all the changes that have and are taking place in the approval process. Through all the proper channels, they have a chance to make it through much easier with some good results in the CLI based measures.
And would the amputation rate be based on the DFU results. If they cure or help the ulcer, would that rate not go down? With no other treatment options, why wouldn't a physician look into other possible treatments, especially if the safety factor is taken out of the equation.
All I'm saying is these fast track and other designations, are not the best for companies like ours, who have spent years going through the proper process, only for some like Celularity to catch up in a much shorter timeframe. Do you not think the ex FDA commissioner on their board, along with many others, increases their chances of success? They use the same sourced cells.
Like I said before, going it alone with be the death sentence of this company imo. In the very least, decreases our chances substantially. Hopefully IC results will get us a big Pharma partner finally. I sure hope we get these in April. Time will tell.
You seem to miss the point that there are other measures that relate to CLI in their study. Is there no possibility of those results point to a positive outcome and possibly even great results. How hard of a jump would it be for an off label type of approval. I do not try to pretend I understand this field. Most is based on logic. With all the fast track, breakthrough designations and such, I think it is extremely possible they could leap frog us in this space. Not going to happen tomorrow, but has the potential to in the not so distant future. It's not like we are likely to fly through our trial, with history being our guide.
It's all possible imo, especially when you look at this companies experience and connections in this industry. The same ones you don't seem to think matters much. As long as they ran a company before, it's good enough for you right?
Do you think they're a threat at all, or do you think they're irrelevant to like many here want to think.
But that proves nothing when it comes to the question I asked. Is that the ONLY answer, bad trial design. Could it not be the therapy itself? I just don't know how you come to that specific conclusion as opposed to your following statement. "This suggests that it's not necessarily treatment/technology specific". Inconclusive results needing larger data sets Could be very well therapy related, not necessarily poor design.
Was waiting for specific points from the actual design, but you just throw out comments to support your thoughts that management doesn't matter.
What's your thoughts on our IC design with walking distance test being our only measured outcome? Is the single outcome used more often than not these days? What happens if they are inconclusive or not off the charts?
Is Meso done now? Did they "not make it". Yes we are doing great without revenue. What stock you looking at? And yes, The twins know what they're doing when it comes to enriching themselves. Board we have has been strategically designed to make sure that happens.
Care to expand on how you came to the conclusion of poor trial design. Or just an assumption. Or flavour of the day?
LMBO. Yes it's laid to rest. Our management is the best. You should be getting th high fives momentarily.
Nothing on all the Celularity discussion right. It's old now I know, so just forget about it. Nothing but jokes from the big gun.
Big guns were brought out for this earth shattering news? Amazing. I guess it is new and price comparing is considered data so...
Ok you guys win. Clearly shows management is irrelevant thank you. Mesoblast is toast and they should just give up now. We have the winners. The countless points that have been brought up about our management and board just disappear because of Mesoblasts hiccup.
Oh, is this good or bad news for us today for the industry? Which one you guys think it should be?b
Yes and Mesoblast sure is getting "crushed". Down 11% in 4 days. What are we down since March 12th? Only 14% decline. Meso still up 20% from Deb 13th. Those numbers sure can be played around with right Saud
And let's not forget about the $14 million in revenue for the last 6 months. You know, the stuff companies try to get and the reason they're created. When you go 15 years without any, it's easy to forget.
See EichKing. NEVER any discussion. Everything is great. We are years ahead of everyone and competition is irrelevant with our lightning speed progression. Our IC trial, was originally thought to be competed the end of 2015. But our CLI trial will fly by.
But Celularity has no idea what they're doing. Only our placenta cells work because we are the best. Good results in their diabetic foot ulcer study couldn't open the door for CLI could it, considering they're looking at similar secondary measures could they. Fast track, accelerated approval, breakthrough designation, compassionate use..all just designed for us. No way they could leap right over us in CLI, all while we try and enrol the first half and then just wait to hear.
And have a look yourself at any indication we have. You know, the ones with some good rodent results. Nobody is ahead of us there. We have orphan drug status!!! Untouchable!!! Only one without much competition is muscle injury following hip surgery. Wonder why?
Management has a good track record of making their estimates right. Our IC trial was supposed to get results the end of 2015 originally. But what's a couple of years in reality. We are light years ahead remember. And we have the right people to ensure we come out on top. End of discussion, for the bitten ones. Especially one post wonder.
And here you go...we'll get em next week. We have all the time in the world.
Good morning Happy,
There is never any discussion from this poster as was shown in their pathetic attempt of a rebuttal. Pretty much the same from many of the posters here.
Why do you never comment on the get a clue comment there Happy. Or was his link from 2014 a good comeback. Funny too, those products that were purchased then are still around and one of them produces revenue for Celularity.
So the lazy comment was pretty justified I think. Did I start off being rude or anything my original post? Proving points on the ineptness of our management is not rude. It's truthful.
Obviously Allo didn't take a look at the link I provided or some comment would have been made between the similarities of the trials. You know, the one where Sellu Hilarity is light years behind Pluristem.
No other response...what a surprise. Waiting to bring out the big gun to counter like the Meso discussion did. Does this topic justify the break in silence. It is about data right. And its new. Aka the double shwammy. We will just have to wait to see if we're blessed with the superhero type response.
I just had a look to see what our primary and secondary outcome measures in our Phase 2 IC. Wanted to see what we can look forward to in April. To my surprise, we only have a primary one only, and here it is.
Log ratio of week 52 maximal walking distance(MWD)to baseline MWD [ Time Frame: 12 months
This is what we are going to see? Could we have been waiting around 5 years and spent a large amount of money on a walk test? I know this is the standard test, as it is the primary measure for most, but surely there has to be some other tests to compare the treatment with. Something a little more scientific, with more conclusive measures. Are they able to report on other things that were not a stated measure? I sure hope so, but not too sure that this could be the case.
Now I looked at many other phase 2'a for comparison. Most had this as their primary outcome. But most had 4 or more others as there secondary outcome. Wouldn't it be better to gain more insight with other measures. Only reason I decided to look into this was from Celularity's trial with the many measures.
Funny the only one I found with one primary and one second that was similar was from Diffusion Pharmaceuticals. A $30 million market cap company. I went through about 15 different ones.
But no, experience means nothing in this industry. On another note, I wouldn't be surprised to see Mark Germain leaving the board. Why would he sell with elections coming up. Hopefully he amd most others do, or at least not get voted back. That includes management.
Let's see some freaking news tomorrow. I'm sick of saying we'll get em next week more than most are tired of seeing it.
For those too lazy to look like the chosen one, here you go.
Time to ulcer closure [ Time Frame: Up to 6 months ]
The time period for the index ulcer to close
Ankle Brachial Index (ABI ) and Toe-Brachial Index (TBI) [ Time Frame: Up to 6 months ]
ABI and TBI will be calculated by dividing the systolic blood pressure at the ankle or toe by the systolic blood pressures (Doppler technique) in the arm
50% Closure of Index Ulcer [ Time Frame: Up to 24 months ]
The proportion of subjects with at least 50% closure of the index ulcer
Transcutaneous oxygen [ Time Frame: Up to 6 months ]
Transcutaneous oxygen measurements determine the oxygen level in tissue below the skin
Time to amputation, ulcer opening closing, gangrene and infection [ Time Frame: Up to 24 months ]
Time to major amputation (above the ankle) of treated leg, minor amputations, to re-opening of ulcer, time to doubling / halving of index ulcer total surface area from baseline, de novo gangrene and foot wound infection
Wagner Grading Scale [ Time Frame: Up to 24 months ]
The Wagner system assesses ulcer depth and the presence of osteomyelitis or gangrene by using the following grades: grade 0 (pre-or postulcerative lesion), grade 1 (partial/full thickness ulcer), grade 2 (probing to tendon or capsule), grade 3 (deep with osteitis), grade 4 (partial foot gangrene), and grade 5 (whole foot gangrene).
Rutherford Criteria [ Time Frame: Up to 6 months ]
The Rutherford classification is a clinical staging system for describing peripheral arterial disease.
36-item Short Form Health Survey (SF-36) [ Time Frame: Up to 6 months ]
A validated measurement of health related quality of life
Diabetic Foot Ulcer Scale Short Form (DFS-SF) index ulcer [ Time Frame: Up to 6 months ]
A measurement of the impact of diabetic foot ulcer on a patient's quality of life.
Patient Global Impression of Change in Neuropathy (PGICN) [ Time Frame: Up to 24 months ]
Assessment of changes in neuropathy over time
European Quality of Life: EuroQOL-5D- health utility index assessment (EQ-5D) [ Time Frame: Up to 6 months ]
A standardized instrument used as a measure of health outcome
Number of all ulcers [ Time Frame: Up to 24 months ]
The total number of ulcers
Leg rest pain score [ Time Frame: Up to 24 months ]
A visual analog scale (VAS) graded from 0 (pain free) to Grade 10 (maximum pain)
No thoughts on the trial I posted. Same irrelevant comeback every time. Go figure. Did you see the common outcomes?
That's an interesting point there EichKing. I wonder what UT gained with respect to the knowledge of our product during their painful partnership with us. Would be interesting to know any connections between UT and Celularity. Phase 1 study from Celularity started 2 years after our partnership was announced.
Like always, I will hope tomorrow continues. But most likely you are right. We will find out soon enough.
For those that think Celularity are miles behind, take a look at their completed phase 2 trial expecting results in November. Enrolled 182 patients. Have a look at the secondary outcome measures and see if you see anything that looks familiar. And remember, they're sourcing their cells from the placenta as well. The link is at the bottom.
Unlike some that think Gottleib is thinking of us when he speaks, I would be more likely listening to one of his predecessors, that sits on Celularity's board.
Competition is everywhere and in every indication. To dismiss this or say good results from others is good for us, it is not. There are too many big companies with deep pockets and incredibly experienced people. Every month or quarter that passes is critical to our existence. To think otherwise is foolish imo. Time is of the essence. In the very least, this year will be telling as to if this company can survive, or fail. We go through this 1st half with nothing significant, look out.
Contrary to what most would believe, I still have some hope and get encouraged a little when we get these mini increases with higher volumes. We need a sustained increase without a raise at the end of it. The silence this year has got to be the worst I have seen yet in my many years.
I always hope that something leaked to someone, and that is the reason for the sudden move out of no where. No computer trading here sorry. You seriously think any company is going to allow any algorithm to trade this stock, when 99 percent of the time it's down to where it was within a couple days. Not a chance. Maybe to short and even then, extremely unlikely.
Our share price is here because of what is "already known" about this company. IC results better be stellar so we can hopefully partner with some big pharma. Going it alone will be our death sentence imo. Too many big players for a small company to survive on its own, especially with little experience.
Efficacy and Safety of Intramuscular PDA-002 in Subjects Who Have Diabetic Foot Ulcer With and Without Peripheral Arterial Disease
https://clinicaltrials.gov/ct2/show/NCT02264288?term=Celularity&rank=5
They should put the upcoming lottery into March's presentation under their milestones. That way, we are GUARANTEED to achieve one AND on time. Only thing for them to decide, is how big a bonus the twins will get. Will they take another 4 million for themselves and let the others feast on the 1.3 million leftovers? They wouldn't be that greedy would they? Still the scratched ones will cheer.
We all understand that this technology is here to stay. Yes there is tons of great news that all substantiates the things to come or that are already here in the field. It's the fact that Pluristem, sits on the sidelines and watches everyone else's good news.
We miss milestone after milestone, with ZERO explanation, update, anything at all. Just a new 12 months at every presentation update. Yes you're good with that we know. As long as there's no bad news. I don't understand how you think a missed timeframe on by almost two and a half times the original six month timeframe is NOT bad news. And that's for preclinical stuff with rodents that don't have enrolment issues that have plagued previous Pluristem trials, and possibly current ones.
Or the almost 3 month over on their interim results for HCT that was promised within 12 months. All we have gotten from the original twin was no safety issues. Woohoooo!!!! Amazing. Incredible stuff. But at least we know they have to have at least 1 person enrolled so far. Thanks Zami.
Or how about the "Huge" Sosei deal. How long does it take to close a deal like that stunner. 14 months and counting. These guys know how to get things done. Sosei just sitting there waiting for IC results before they take the plunge? Seems to be the case. Will they get the same whopper of $11 million to startup "Newco" like the original agreement states? Or will the much reduced risk of knowing phase 2 results, increase this "deal" substantially if we get good results. If they don't get a substantial increase in the terms of this deal, management is far worse than I ever imagined. Did Pluristem not have any outs in their agreement? Who knows, experience doesn't matter in Biotech.
Or the 5% dilution event to award stocks instead of options, we are going to see in a couple months. Great news!!!
Or the selling of shares by one of our directors. Amazing news as well. Whew, finally they can get on with the good news, now that the sell occurred. But yet most praise to this type of hype. Silence speaks volumes on that one.
But we've gotten so much great news so far this year, it doesn't matter. Our original twin coming out and saying they made most milestones is what you want from leadership. Taking some moves right out of Trump's playbook. Hey if it's works for his base, it's good for the scratched ones here as well. Next quarter we will rule right? Just pretend that line is their presentation. That way it moves in conjunction with their presentations. And makes everyone Happy!!!
That poster you want to back said they only looked at the abstract. Do you really think that is true? This is the one that tells everyone to get a clue because he knows everything right. The moment I saw his claim of "huge" I looked at the article. As soon as I saw it was about medium, I wondered what medium Pluristem used. A search of Pluristem medium took me to the truth. Pretty simple huh. There's zero chance they were trying to mislead right. For the bitten ones at least.
And of course this comes from the one with self admitted multiple aliases, deleted posts on a mass scale every other week. But none of that matters. It was just a simple mistake right. That proves nothing of Thor agenda right. Just a simple poster, doing what I mentioned above, yes no care about it at all. Just praise. Good for you. But yet you wonder why you get painted with a suspicious brush. You want to reply to this, at least let us know your thoughts on the chosen one posting under multiple aliases of their deletion of posts. I smell some silence coming up because I'm rude and hurt feelings. Just like your best bud.
It is hard to come up with something original huh. But imitation is the sincerest form of flattery right. So thank you. Saying it 20 times is not original. Saying you're good with management and the performance of this stock isn't either. We all know who the bitten ones are, and I think they took a chomp out of you. Hook line and sinker. Nothing bad at all. All good here. Nothing to see, move along.
Wanted nothing more than to wait for you to chime in on the fake "this is unbelievable" news we had. Can only imagine your take on the medium. Would have been just as "enthusiastic" as the one that posted, if not more. Some cut and copies, a couple of thoughts with some thesaurus words. Classic!!! But I spared you the shame. You're welcome.
LMBOx200,000-194,000. Because they bought into the mini pump.
I bother because of some that claim a pursuit of 200,000 shares. Now why would someone say that? Lot of "misinformation" on this board from the scratched or bitten ones, that have joined the Pluristem zombie apocalypse. You're copying of people's remarks must be what Yaki let rip in front of reporters then.
Spelling ya right. They search all the time and that whole article was on the "medium". Not a single mention of 3D. But everything is good news for us when it comes to others good fortunes. Who cares if we don't join in the party. It's Biotech!!!
LMBOx200,000-194,000. Because they added during the last mini pump.
Wow this is going to be HUGE!!! It's a sad state when someone posts something and everyone jumps all over it in desperation to try and justify their persistent beliefs in this company, and even more specifically, management and board. See we were right!!! We're going to win!!! They were wrong!!! Management rules!!! They're useless, accept it.
I'm sorry to burst the profound enthusiasm this Friday night, but one link will get you back to the we'll get em next quarter frame of mind that we've been in for many years now.
http://www.emdmillipore.com/CA/en/product/PluriSTEM-Human-ES/iPS-Medium,MM_NF-SCM130
Way to get out in front of it. Yes this is amazing news isn't it. They've just been waiting for him to sell. Now they can get things moving. Incredible sign I must agree. Hopefully we get more insider selling as this is usually a good sign of things to come.
Besides, he should win another 50,000 to 100,000 when the annual Pluristem, everyone wins, lottery that comes to Israel in a couple of months. I'm sure all the hard work he has done on behalf of shareholders is worth the $750,000 he has won off the backs of shareholders.
And here I thought we'd see some insider buys. Give my head a shake. What was I thinking.
We'll get em next week. Soon we can give the get em next quarter. I'm good with them all
The You always tout the possible benefits to Pluristem's therapies when you post these types of articles. But there is also one very important part you leave out. It bodes well for ALL companies in these spaces.
Could there be a phase 1 trial out there that had tremendous success? Could they now, or soon, get some sort of conditional approval? I'm not saying there is, but it is quite possible don't you think. Companies with deep pocket all realize this and are scrambling to get their products out to the masses as well. All vying for the riches this industry will see. In essence, it kind of sucks for the companies that have spent millions of dollars and years of work, only to have a company step right in and leapfrog a company with early, statistically insignificant results. Personally I find this more of a threat to our company, rather than helping.
Or what if we did get approval in something. How long before a competitor can come around and get something to market relatively quickly. Big company with big marketing could erase a small companies lead rather quickly. Could big pharma be pushing for this type of legislation with this in mind? Again, not really a fan of this from an invesent point of view anyway.
You want to sit there and put down Celularity saying they are years behind right. They are using the same cell source as us right. Do you think they don't know about changes that are coming. Do you not think this is a reason for the hype or the funding they received. The people at their top probably come from engineering backgrounds too right. No vast knowledge of the industry, no relationships formed in every area of Big Pharma, government, FDA. No they're going to sit back and go through the same painful 10 years of trials like we have. But we have patents. They only have 800
But yes, I'm sure the tortoise always wins right. Those that still believe this management is capable, best of luck. Unfortunately we need some serious luck to fall out way with the management team we have in place.
I'm curious to see what happens tomorrow. We did have a nice little gain on high volume. Do we drift right back to much lower volumes. We will see. Certainly hope not. Did out ATM kick in today. I can't stand not being able to find that out.
But there is, imo, an sense of urgency with this management. The AGM is a short few months away. Does anyone think they want to head in there with a price in the $1.30's. How would 5.3 million free shares to the employees sit with the Israeli investors, or any investor in reality. Aside from the usual crew here, it will be hated worse than the 4 million to the twins.
It is a little strange the Chinese show disappearing. Do we see a partnership that is actually signed, or the dreaded binding term sheets. How they're called binding makes no sense to me.
I. wouldn't be surprised to see some insider buys coming through. I truly believe they are feeling some fire under their a$$. Rightfully so.
Whatever it is it better come soon. 2018 has been a bust so far. Soon enough the first quarter of the year will have come and gone. Nothing unusual about that with these guys. Give us some news please...we deserve something don't you think.
Some just don't know when to tap out there EichKing. Even quotes the SAME article as the previous one. Now that's research. Find one and stick to it. They will of course get the usual praise by one no doubt. Suddenly have a hankering for some strudel.
First tried to argue the cost of Car~t, now safety. I'm sure the medical world will just sit still on that one. Side effects are there and will be forever. No screening techniques will be used to understand who may be susceptible. No treatment for the side effects will ever be tried, it just is what it is. A simple cognitive 10 point test couldn't possibly be used to try and catch the symptoms early, making treatment easier. That's the stuff of science fiction.
But I'm sure if the resident car-t expert here actually knows a thing or two about the topic, They must already be well aware of what's happening with that therapy. Just gets conveniently left out in the never ending, repetitive attempt to justify their point. .
Yet all along, totally dismiss the fact that this therapy is here now, while we have a possibility to change rodents outcomes from this deadly disease as I write this. Incredible!!!! According to The chosen one, we should probably get approval next week.
I'm no expert by any means, but a few simple searches can shed light on the subject. No need for me to try and change wording around to make me sound like an expert. Just get burned doing that, each and every time.
Big bucks involved, big money being spent to find the solutions to it all. We have the twins on the world tour, winning lotteries year after year. I'm good with that of course.
And that brings us to the forever shunned topic of management. Avoid at ALL costs. Argue others therapies, just say ours has no bad data yet. That will keep the dogs at bay. Oh he made fun of me...I'm not going to answer...I'm the only one allowed to do that...where's my pacifier...I'm upset now.
What a jump we had today. Tons of block trades going through. Someone MUST be accumulating. LMBOx200,000-195,000. You know why.
For those that want to look at our pathetic tute ownership, found the most up to date site I have seen yet. Here's the link for your pleasure/misery. Ownership down 4.83%.
https://fintel.io/so/us/psti
No worries. Wouldn't expect anything else but wash rinse repeat.
Some words I found from the first born. Highly touts the speed of Japanese pathway. Did I miss the technique he spews? Design of the trial was accepted by the PMDA back in Dec of 2015. Wonder why partnerships elude us. Stuck in the twilight zone he is. This guy is truly delirious and an absolute joke. .
“The improvement of our CLI program in the course of the speeded up regulatory pathway may just permit a extra fast front into the sizeable Jap marketplace, as has been our technique,” mentioned Zami Aberman, Pluristem’s chairman and CEO.
https://nextstepnews.website/business/how-japan-is-creating-new-opportunities-in-the-field-of-regenerative-medicine-sponsor-content-from-the-government-of-japan/
There is competition on every front. Not sure the twins grasped this as there has never been a sense of urgency whatsoever. Go for a couple orphan drug status', then leave them on the shelf. Complete waste of time unless you are going to pursue, which they didn't on two of them. Just fluff imo, in an attempt to increase price for their dilutions.
They have not done well by any means on the partnership front in the past. Only way I see even remotely changing is with IC results. If we see them and they're good, that Sosei deal better be a heck of a lot better than what it is. Otherwise these guys are complete fools. We should find out in April, but with the way these guys miss targets, it's a crap shoot.
And I can't see us being anywhere close to $5 this year. Even with $50 million funding for ARS, I don't think we'd get much above 2. But I would love nothing more than for me to be wrong on everything.
If you actually read my post, I was referring to anyone who tries to justify management as jokes. Not the person I was responding to. They were ok with the competition in oncology. Nobody these days seems to even attempt to justify these clowns any more. Have you?
You consistently complain about the same posts over and over again. Have you ever actually read your own posts. Aside from having to wade through the copy and pastes of other posters, you pretty much have stated nothing new for a very long time. The same old good results...good results...good results. Those good results have done jack for our price.
But we have 5.3 million shares locked and loaded for the Pluristem lottery. You're good with that I'm sure. Again, I am not.
And I hate to tell you, using big words or relatively unknown words, doesn't make your posts sound better.
I was mainly referring to oncology subject. But if you want to look at CLI, 31 phase 3 trials listed. With what results, I don't know. But a lot of competition nonetheless.
With regards to manufacturing, I have shown how others do it now. Only advantage we will have is we cut out having to outsource manufacturing. But others are manufacturing themselves, utilizing technologies from others.
Manufacturing for Pluristem will remain useless, until they get a product to market. Well not entirely, as they don't have a significant manufacturing cost for their own trials. ARS really is their only near to mid term hope. Without something from ARS, they will need significantly more funds. $50 million according to Edison report, by 2020.
If you want to respond, try to counter THIS argument about THIS post, and not come up with something totally different, as you have a tendency to do.
Why? The company you try to use as a comparison to our CLI trial and the speed we will get there, doesn't seem to fit your thought of approval coming quickly for us.
They got fast track in 2003, orphan drug status in 2014, initial phase 3 results in May of 2016, breakthrough designation May 2017, priority review, June 2017, and approval today.
But miraculously we are going to fly to approval. No matter what, we have a long way to go. So before you throw out clueless, research what you point out. Or do the facts I present, support your argument?
And besides, that's why they haven't updated clinical trials site since Jan of this year. Where's the 40 sites coming.
Or why are they offering rsu' sin stead of the more palatable options? If something big we're to be coming, I'm sure employees would be motivated by options alone. But ya, any day now.
No we are not alone on anything. Really look around at the biotech industry. Trials everywhere advancing. Big Pharma doesn't sit still because we have "the best" technology. Do a search on clinical trials site. Triple negative breast cancer. 498 trials, 49 in phase 3. Solid tumours. 4189 trials, 177 phase 3's.
How far do you think Pluristem is away from ever having a shot at this? They did this so they have an "oncology" product, in the hopes that it would garner attention. It didn't. Nothing does. No controller necessary here. Sleeping giant is one fail away from life support.
We are in a time of medical miracles coming from everywhere. Companies with deep pockets, experienced management, and the know how to advance their products quickly. We have the "fast track" on several, but just like the PMDA that's been sitting idle for years, we just move along at a normal pace. We are not alone in getting these "fast track" designations. Do you think others are moving slowly like we are. I don't. We are what, 2 years waiting for Sosei to close. Pathetic.
IC results better be stellar to say the least. Mediocre results just won't cut it. They need great results to increase share price for further dilutions, or that promised partnership they've been touting for many years now. Failing that, it would leave us with ARS as our only hope, without more increasingly painful dilutions to get through to the half way point to CLI. And if IC results aren't that great, what hope is there for CLI.
As always, we have to wait and see, all while others catch up and/or overtake us on our products. Management did us no good in their 2 year delay in building out manufacturing. Time is of the essence and they made poor decisions that have put our price where it is. Stagnant like nothing else I have ever seen in the biotech space.
So no, we are not alone and I'm truly NOT ok with it. How anyone justifies this management and the decisions they have made is remarkable. I guess that's why nobody does with any claims other than they're "ok" with it. Jokes.
As long as the data is good thats all that matters.
Zero experience in management or board, cash on hand, burn rate, missed milestones, no partnerships, future dilutions, upcoming bonuses, real possibility of a r/s, fact that all data is from small populations, zero interest in this stock when most are buzzing with potential, inept PAST performance from the clowns running the company, same price for the last 10 years, all of it,,,Irrelevant.
When logic is ignored, the illogical controller conspiracy must be the only conclusion.
LMBO 200,000-195,000. Even if I don't throw it in there the questions are still ignored. Because there are no comebacks to the important, highly relevant questions. Thin skins are growing exponentially here. The one who dishes it the most, can't take it in return.
Should we cheer the lower price after hours? AH or not, it's still in the wrong direction. With a little more volume than the normal 100 to 200 shares. But the lower it goes, the same will continue to say anything under ... Is a steal. It could drop under a buck and you will still be "loading up" right.
Glad your boy Spidey went back into not answering my questions directed at him. It was after all, a little embarrassing watchim them try to counter the argument last week. Way to hide Spidey.
I Don't If Others Try Sometimes
The whole world doesn't see it. Management, analysts, sec, nobody. Only one, perhaps 2 here now do. Funny how no other big Pharma company doesn't see the "disruptive technology" Pluristem possesses. But only one does according to your theory.
But I guess they don't have the pharma experience like out twins have. They just hand out degrees to anyone from Yale and Harvard. Pretty much anywhere except Israeli schools. No alumni have ever made anything coming from these places. That's why nobody else can see it except our twins and ONE other big pharma.
It's not like they haven't been out to every show in the world for the past 10 years. Every investor, biotech and manufacturing show imaginable.
It is well known about the manipulation that goes on in the TASE. Is it not possible these same manipulators could trade on the Nasdaq as well to help with their agenda? Or how about some people with an agenda closer to home? Some could actually use these boards as well to further them. Nah!!! It must be a controller. No other possibilities whatsoever LMBO.
Funny how nobody else but a select few ever post on this topic that comes up consistently. Wonder why. Hmmmmmm.
No you thought wrong. I said and meant that in one month and they have a product that could be approved next month. Good job on the psychological purpose for posting. We have yet to start our trial. So thanks.